| Name | Title | Contact Details |
|---|
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Our mission is to create tools that empower physicians and consumers by increasing their access to actionable data.
ReadCoor is leading the next generation of `omics` by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with a fundamental new technology called FISSEQ which simultaneously enables integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of `In-situ Sequencing` and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insight. ReadCoor will fulfill the mission with a comprehensive set of high quality services, systems and actionable information provided to research and healthcare communities worldwide. Current transcriptomic tools are cumbersome, inadequate and cannot preserve the rich panomic information contained in cellular structures. ReadCoor combines both next generation sequencing and morphometric information for the first time in a new generation sequencing platform that enables researchers to perform high throughput RNA sequencing without dissociating cells, thus preserving important cellular structures, pinpointing transcripts to individual cells in 3D, and delivering high fidelity spatial image data.
Transforming cancer care with data driven medicine
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.